RNA Therapy Clinical Trials Market Size & Share, By Modality, Phase, Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological) - Growth Trends, Regional Insights (U.S., Japan, South Korea, UK, Germany), Competitive Positioning, Global Forecast Report 2025-2034

Report ID: FBI 5158| Published Date: Jan-2025| Format: PDF, Excel
Jump to Content
Market Outlook

Market Size and Growth Outlook

RNA Therapy Clinical Trials Market size is expected to see substantial growth, increasing from USD 2.8 billion in 2024 to USD 4.07 billion by 2034, at a CAGR of over 3.8%. By 2025, the industry revenue is estimated to be USD 2.9 billion.

Base Year Value (2024)
USD 2.8 billion
CAGR (2025-2034)
3.8%
Forecast Year Value (2034)
USD 4.07 billion
Historical Data Period
2019-2024
Largest Region
North America
Forecast Period
2025-2034

Get more details on this report

Request Free Sample Report
Snapshot

RNA Therapy Clinical Trials Market Intelligence Snapshot

Regional Market Dynamics

Segment Momentum

Market Expansion Drivers

Leading Market Participants

Forecast Snapshot

Global Market Forecast Snapshot

Market Outlook

Regional and Segment Outlook

Market Dynamics

Market Growth Drivers and Industry Trends

Growth Drivers & Opportunity: A major contributor to the growth for the RNA therapy clinical trials market is the increasing prevalence of genetic disorders and chronic diseases. With a considerable rise in the incidence of conditions such as cancer, genetic syndromes, and viral infections, there is a growing demand for innovative treatment options that can directly target disease-causing genes. RNA therapies, which include RNA interference (RNAi) and messenger RNA (mRNA) therapies, offer a novel approach to modulate gene expression and provide therapeutic effects at a genetic level, thus capturing the attention of researchers and pharmaceutical companies alike. Another significant growth driver is the advancements in RNA delivery technologies. Innovations in nanoparticle-based delivery systems and lipid nanoparticles have improved the efficacy and safety of RNA therapeutics, enabling the successful transport of RNA molecules to the intended target cells. These advancements are crucial for overcoming previous limitations associated with RNA therapies, such as stability and cellular uptake, thereby paving the way for more robust clinical trials and a larger number of potential therapies entering the market. The third driver is the favorable regulatory environment surrounding RNA therapies. Regulatory agencies such as the FDA have recognized the potential of RNA-based treatments and are streamlining the approval processes for these innovative therapies. Initiatives promoting fast-track designations and breakthrough therapy designations for RNA therapies are significant incentives for biopharmaceutical companies to invest in clinical trials, thus contributing to market growth. Industry Restraints: A major restraint in the RNA therapy clinical trials market is the high cost associated with research and development. RNA-based therapies require substantial investments in terms of technology, skilled labor, and regulatory compliance, which can deter smaller companies and startups from entering the market. The complexity of designing and conducting clinical trials for RNA therapies, combined with the lengthy timeline for regulatory approvals, can also impose financial challenges that limit the overall growth potential of the market. Moreover, another significant challenge is the public perception and safety concerns related to RNA therapies. The market has faced skepticism regarding the long-term effects and potential risks associated with the use of RNA therapeutics, particularly those involving genetic modifications. Concerns related to off-target effects, immune responses, and ethical implications surrounding gene therapies can impact patient acceptance and participation in clinical trials, thus hindering market expansion.

Explore Growth Opportunities

Request Free Sample Report
Regional Forecast

Regional Demand Dynamics

RNA Therapy Clinical Trials Market
Largest Region
North America
37% Market Share in 2024
North America: The North America RNA therapy clinical trials market is driven by the presence of a well-established healthcare infrastructure and high prevalence of chronic diseases in countries such as the U.S. and Canada. The market is characterized by a strong focus on research and development activities, leading to a high number of clinical trials being conducted in the region. Additionally, the presence of key market players and collaborations with academic and research institutions further contribute to the growth of the RNA therapy clinical trials market in North America. Asia Pacific: The Asia Pacific RNA therapy clinical trials market is witnessing significant growth, especially in countries like China, Japan, and South Korea. Factors such as a large patient pool, rising healthcare expenditure, and increasing awareness about RNA therapy are driving the market in this region. Furthermore, government initiatives to promote clinical research and development activities are also boosting the growth of the RNA therapy clinical trials market in Asia Pacific. Europe: Europe is a key region in the global RNA therapy clinical trials market, with countries like the United Kingdom, Germany, and France leading the way. The market in Europe is characterized by a strong regulatory framework, advanced healthcare infrastructure, and a well-established pharmaceutical industry. These factors make Europe an attractive destination for conducting RNA therapy clinical trials. Additionally, increasing investments in research and development activities and collaborations between industry players and research institutions are further propelling the growth of the RNA therapy clinical trials market in Europe.
🔒 Need data on a specific country or region? Individual country/region reports are available at discounted pricing. Inquire Before Buying

Go beyond the chart, access full insights & data tables

Request Free Sample Report
Modality: RNA Therapy Clinical Trials Market by Modality: The RNA therapy clinical trials market can be segmented by modality into oligonucleotide-based therapies and mRNA-based therapies. Oligonucleotide-based therapies involve the use of short DNA or RNA molecules to target specific genes or proteins in the body, while mRNA-based therapies utilize messenger RNA to instruct cells to produce therapeutic proteins. Both modalities show promising results in various therapeutic areas, driving the growth of the RNA therapy clinical trials market. Phase: RNA Therapy Clinical Trials Market by Phase: The RNA therapy clinical trials market can also be segmented by phase into phase I, phase II, and phase III clinical trials. Phase I trials focus on the safety and dosage of RNA therapies in a small group of patients, while phase II trials evaluate the efficacy and side effects in a larger group. Phase III trials further confirm the safety and efficacy of RNA therapies in a larger patient population. The different phases of clinical trials play a crucial role in determining the success and market approval of RNA therapies. Therapeutic Areas: RNA Therapy Clinical Trials Market by Therapeutic Areas: The RNA therapy clinical trials market can be categorized into rare diseases, anti-infective, anticancer, and neurological therapeutic areas. RNA therapies show great promise in treating rare diseases by targeting specific genetic mutations, providing hope for patients with rare and often incurable conditions. In the anti-infective therapeutic area, RNA therapies hold potential for developing novel treatments for infectious diseases by targeting the genetic material of pathogens. Anticancer RNA therapies target cancer cells with precision, offering new treatment options for cancer patients. In the neurological therapeutic area, RNA therapies show potential for treating neurodegenerative disorders by targeting specific genes involved in disease progression. The diverse therapeutic areas supported by RNA therapies highlight the versatility and broad applicability of this emerging treatment modality in clinical trials.
Segment Sub-Segment Largest Segment Fastest Growing
Custom Research

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
Competitive Landscape

Competitive Landscape and Market Positioning

The RNA Therapy Clinical Trials Market is characterized by intense competition among biotechnology and pharmaceutical companies focused on harnessing RNA-based technologies for therapeutic applications. The landscape is marked by a growing number of clinical trials aimed at treating various diseases, including genetic disorders, cancers, and viral infections. Major players are investing heavily in research and development to advance their RNA therapy candidates through various phases of clinical trials. Collaborations and partnerships between companies, as well as with academic institutions, are increasingly common to leverage expertise and resources. As regulatory frameworks evolve to accommodate these innovative therapies, the competitive dynamics are expected to shift, with an emphasis on breakthrough therapies and personalized medicine. Top Market Players - Alnylam Pharmaceuticals - Vertex Pharmaceuticals - Moderna - BioNTech - Arcturus Therapeutics - Sarepta Therapeutics - Isis Pharmaceuticals (Ionis Pharmaceuticals) - Silence Therapeutics - Exicure - Translate Bio
Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Report Customization

Customize Your Report

Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.

1 Custom Segments 2 Custom TOC 3 Related Reports

RNA Therapy Clinical Trials Market — Custom Segments

Segment Sub-Segment
No segment data available.

RNA Therapy Clinical Trials Market — Custom TOC

Custom Chapter Chapter Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
FAQ

Frequently Asked Questions

Testimonials

Our Clients

"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."

Project Manager
Siemens Healthcare

"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."

Research and Development (R&D) Manager
GC Biopharma

"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."

Quality Assurance Manager
Medtronic
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL
Healthcare & Medical Devices
Research Team Overview

This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team
10+Industry Verticals
100+Countries Analyzed
5-7Days Standard
Delivery
13.8K+Research Reports
Published
On-DemandCustomized Research
Available
6Months Analyst
Support
PDF + XLSReport Deliverables
Trust & Compliance
D&B D-U-N-S
GDPR & CCPA Compliant
ISO 9001 Certified (ISO 9001:2015)
SSL Encryption
Secure Payments
Confidential Handling
Research Intelligence
Primary Research Network
Secondary Sources
Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts
Research Workflow & Quality Assurance
01
Data Collection
Verified information gathered through primary and secondary research.
02
Data Triangulation
Cross-validation using multiple independent data sources.
03
Forecast Modelling
Market estimates developed using historical trends and analytical models.
04
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
05
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
06
Final Publication
Released after successful completion of the internal review process.
Report Coverage
Market Assessment
  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics
🏢 Competitive Intelligence
  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis
🚀 Future Outlook
  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →